LINC00869

Across TCGA pan-cancer cohorts, LINC00869 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LINC00869 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LINC00869 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC00869 expression acts as an unfavorable survival marker.

OV, COAD, and UCEC are the cancer types where LINC00869 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.222	0.541	.038	18	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LINC00869–OV (DFS)

Open the OV breakdown →